zopiclone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
hypnotic tranquillizers 2873 43200-80-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • zopiclone
  • zimovane
  • imovane
S(+)-enantiomer of racemic zopiclone; azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; was term of zopiclone 2004-2007
  • Molecular weight: 388.81
  • Formula: C17H17ClN6O3
  • CLOGP: 1.25
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 0
  • TPSA: 91.76
  • ALOGS: -2.64
  • ROTB: 3

Drug dosage:

DoseUnitRoute
7.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.12 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 4.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.28 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 1.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.20 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 15, 2004 FDA SUNOVION PHARMS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Intentional overdose 766.01 10.52 706 72419 64238 46548699
Intentional self-injury 598.47 10.52 407 72718 23759 46589178
Coma 555.34 10.52 564 72561 57785 46555152
Somnolence 291.63 10.52 710 72415 155811 46457126
Pneumonia aspiration 283.26 10.52 296 72829 31309 46581628
Poisoning deliberate 221.47 10.52 144 72981 7782 46605155
Toxicity to various agents 188.27 10.52 742 72383 211024 46401913
Lower respiratory tract infection 184.76 10.52 319 72806 54770 46558167
Suicide attempt 181.06 10.52 316 72809 54720 46558217
Product dose omission issue 162.71 10.52 33 73092 168487 46444450
Muscle spasticity 147.61 10.52 131 72994 11309 46601628
Drug ineffective 136.34 10.52 574 72551 677264 45935673
Akathisia 125.60 10.52 101 73024 7613 46605324
Body temperature increased 122.56 10.52 172 72953 24689 46588248
Ear pain 121.24 10.52 161 72964 21931 46591006
Confusional state 119.81 10.52 532 72593 159360 46453577
Depressed level of consciousness 118.97 10.52 243 72882 47326 46565611
Electrocardiogram QT prolonged 111.96 10.52 248 72877 51077 46561860
Hyponatraemia 108.19 10.52 377 72748 100955 46511982
Electric shock 105.07 10.52 43 73082 864 46612073
Death 102.00 10.52 235 72890 335313 46277624
Drug hypersensitivity 101.81 10.52 140 72985 243685 46369252
Overdose 97.49 10.52 366 72759 101613 46511324
Insomnia 88.26 10.52 499 72626 164425 46448512
Respiratory disorder 84.89 10.52 153 72972 27147 46585790
Hepatocellular injury 83.70 10.52 159 72966 29363 46583574
Suicidal ideation 81.50 10.52 233 72892 56149 46556788
Cardiac failure congestive 78.67 10.52 23 73102 91727 46521210
Antipsychotic drug level increased 74.79 10.52 52 73073 3140 46609797
Prescription form tampering 74.57 10.52 31 73094 649 46612288
Drug dependence 70.30 10.52 118 73007 19783 46593154
Altered state of consciousness 59.21 10.52 120 73005 23228 46589709
Night sweats 58.64 10.52 131 72994 27119 46585818
Intervertebral discitis 56.32 10.52 40 73085 2499 46610438
Post-traumatic stress disorder 55.52 10.52 48 73077 4000 46608937
Mydriasis 54.98 10.52 75 73050 10478 46602459
Alopecia 54.01 10.52 108 73017 162306 46450631
Injection site pain 53.83 10.52 53 73072 107099 46505838
Somnambulism 52.08 10.52 51 73074 4986 46607951
Drug intolerance 50.44 10.52 96 73029 146953 46465984
Disturbance in attention 50.11 10.52 135 72990 31425 46581512
Lupus vasculitis 49.98 10.52 21 73104 452 46612485
Depressed mood 48.43 10.52 138 72987 33181 46579756
Treatment failure 47.97 10.52 45 73080 93042 46519895
Mental status changes 47.71 10.52 3 73122 38085 46574852
Schizoaffective disorder 47.10 10.52 29 73096 1423 46611514
Hypothermia 46.76 10.52 75 73050 12108 46600829
Cholestasis 46.75 10.52 119 73006 26774 46586163
Agitation 46.51 10.52 191 72934 55224 46557713
Hallucination 45.81 10.52 177 72948 49774 46563163
Miosis 45.25 10.52 54 73071 6603 46606334
Drug interaction 44.44 10.52 500 72625 202594 46410343
Asphyxia 42.61 10.52 47 73078 5279 46607658
Maternal exposure during pregnancy 41.61 10.52 60 73065 102489 46510448
Disease progression 40.52 10.52 50 73075 91250 46521687
Fluid retention 39.88 10.52 15 73110 51031 46561906
Muscle injury 39.03 10.52 43 73082 4823 46608114
Abdominal discomfort 38.82 10.52 115 73010 151050 46461887
Inappropriate antidiuretic hormone secretion 38.79 10.52 75 73050 14027 46598910
Demyelination 38.48 10.52 46 73079 5634 46607303
Folliculitis 38.40 10.52 48 73077 6155 46606782
Nightmare 38.21 10.52 82 73043 16516 46596421
Tachycardia 36.97 10.52 275 72850 99347 46513590
Antipsychotic drug level above therapeutic 36.27 10.52 21 73104 920 46612017
Lactic acidosis 36.00 10.52 126 72999 33783 46579154
Sinus rhythm 35.95 10.52 18 73107 587 46612350
Synovitis 35.83 10.52 26 73099 61049 46551888
Fall 35.69 10.52 718 72407 328379 46284558
Dysarthria 35.30 10.52 134 72991 37364 46575573
Gastrooesophageal reflux disease 35.22 10.52 218 72907 74126 46538811
Temperature intolerance 35.08 10.52 51 73074 7556 46605381
Coordination abnormal 34.84 10.52 62 73063 10887 46602050
General physical health deterioration 34.51 10.52 304 72821 115465 46497472
Mania 33.98 10.52 61 73064 10785 46602152
Psychiatric symptom 33.10 10.52 38 73087 4459 46608478
Injection site erythema 32.77 10.52 41 73084 74386 46538551
Unevaluable event 32.21 10.52 16 73109 46159 46566778
Injection site reaction 31.29 10.52 18 73107 47831 46565106
Extrapyramidal disorder 31.08 10.52 60 73065 11208 46601729
Therapy cessation 30.82 10.52 3 73122 26626 46586311
Progressive multifocal leukoencephalopathy 30.79 10.52 60 73065 11286 46601651
Injection site bruising 30.41 10.52 9 73116 35627 46577310
Hyperhidrosis 30.05 10.52 241 72884 89067 46523870
Hallucination, visual 29.94 10.52 78 73047 17795 46595142
Drug level above therapeutic 29.88 10.52 32 73093 3477 46609460
Pemphigus 29.65 10.52 17 73108 45257 46567680
Sputum discoloured 29.27 10.52 63 73062 12715 46600222
Blood creatine increased 29.19 10.52 36 73089 4554 46608383
Therapy non-responder 29.10 10.52 14 73111 41138 46571799
Neutrophil count increased 28.97 10.52 67 73058 14186 46598751
Gallbladder adenocarcinoma 28.85 10.52 9 73116 78 46612859
Urticaria 28.41 10.52 296 72829 117596 46495341
Bezoar 28.39 10.52 21 73104 1398 46611539
Antidepressant drug level above therapeutic 28.19 10.52 13 73112 352 46612585
Toxicologic test abnormal 28.01 10.52 16 73109 683 46612254
Sepsis 27.83 10.52 114 73011 135900 46477037
Hospitalisation 27.82 10.52 35 73090 63350 46549587
White blood cells urine positive 27.44 10.52 33 73092 4067 46608870
Drug level increased 27.40 10.52 77 73048 18364 46594573
Broncholithiasis 27.36 10.52 9 73116 94 46612843
Eczema 27.25 10.52 82 73043 20318 46592619
Diaphragmatic rupture 27.16 10.52 11 73114 215 46612722
Cognitive disorder 27.00 10.52 122 73003 36761 46576176
Orthostatic hypotension 26.49 10.52 92 73033 24566 46588371
Psoriatic arthropathy 26.30 10.52 12 73113 36367 46576570
Red blood cells urine 25.99 10.52 13 73112 423 46612514
Myocardial infarction 25.90 10.52 73 73052 97455 46515482
Adverse drug reaction 25.87 10.52 19 73106 44343 46568594
Lupus nephritis 25.61 10.52 24 73101 2222 46610715
Balance disorder 25.59 10.52 181 72944 64340 46548597
Bronchial wall thickening 25.45 10.52 16 73109 815 46612122
Excessive eye blinking 24.87 10.52 14 73111 581 46612356
Disorientation 24.73 10.52 119 73006 36799 46576138
Injection site pruritus 24.53 10.52 16 73109 39727 46573210
Premature delivery 24.24 10.52 3 73122 22066 46590871
Agitation neonatal 24.18 10.52 13 73112 492 46612445
Wrong technique in product usage process 23.93 10.52 30 73095 54392 46558545
Product quality issue 23.90 10.52 13 73112 35635 46577302
Toxic skin eruption 23.84 10.52 57 73068 12330 46600607
Psoriasis 23.83 10.52 55 73070 78549 46534388
Malaise 23.79 10.52 683 72442 330549 46282388
Systemic lupus erythematosus 23.71 10.52 41 73084 65139 46547798
No adverse event 23.67 10.52 12 73113 34219 46578718
Adverse event 23.61 10.52 12 73113 34172 46578765
Urinary retention 23.60 10.52 92 73033 25969 46586968
Plasma cell myeloma 23.50 10.52 21 73104 44457 46568480
Drug reaction with eosinophilia and systemic symptoms 23.34 10.52 100 73025 29448 46583489
Coronary artery disease 23.08 10.52 12 73113 33740 46579197
Cerebrovascular accident 23.05 10.52 81 73044 100958 46511979
Aggression 22.84 10.52 83 73042 22661 46590276
Wrong rate 22.72 10.52 7 73118 58 46612879
Abortion spontaneous 22.59 10.52 21 73104 43625 46569312
Ataxia 22.52 10.52 60 73065 13870 46599067
Lymph node calcification 22.45 10.52 9 73116 171 46612766
Behaviour disorder 22.44 10.52 21 73104 1940 46610997
Full blood count decreased 22.14 10.52 4 73121 22207 46590730
Monocyte percentage increased 22.14 10.52 16 73109 1027 46611910
Hypocoagulable state 22.09 10.52 16 73109 1031 46611906
Hypersensitivity vasculitis 21.99 10.52 30 73095 4191 46608746
Malignant polyp 21.71 10.52 9 73116 187 46612750
Parkinsonism 21.53 10.52 42 73083 7906 46605031
Hypotension 21.48 10.52 496 72629 232093 46380844
Psychotic disorder 21.42 10.52 81 73044 22540 46590397
Urine leukocyte esterase positive 21.37 10.52 23 73102 2512 46610425
Hypersensitivity 21.20 10.52 143 72982 150178 46462759
Salivary hypersecretion 21.16 10.52 37 73088 6408 46606529
Poor feeding infant 20.99 10.52 9 73116 204 46612733
Procedural anxiety 20.97 10.52 12 73113 514 46612423
Pneumonia 20.94 10.52 440 72685 375880 46237057
Urine abnormality 20.87 10.52 34 73091 5560 46607377
Coma scale abnormal 20.85 10.52 32 73093 4974 46607963
Negative thoughts 20.65 10.52 14 73111 811 46612126
Learning disorder 20.42 10.52 11 73114 418 46612519
Loss of consciousness 20.35 10.52 259 72866 107979 46504958
Rash maculo-papular 20.25 10.52 92 73033 27782 46585155
Postmortem blood drug level abnormal 20.20 10.52 10 73115 318 46612619
Knee arthroplasty 20.15 10.52 6 73119 23659 46589278
Scratch 20.14 10.52 31 73094 4831 46608106
Delusion 19.95 10.52 50 73075 11138 46601799
Hand deformity 19.91 10.52 15 73110 34559 46578378
Peripheral circulatory failure 19.86 10.52 10 73115 330 46612607
Agranulocytosis 19.83 10.52 78 73047 22107 46590830
Fluid overload 19.60 10.52 9 73116 27176 46585761
Crystal urine present 19.47 10.52 16 73109 1243 46611694
Hypochloraemia 19.43 10.52 19 73106 1854 46611083
Psychotic symptom 19.41 10.52 14 73111 896 46612041
Myelocyte percentage increased 19.40 10.52 8 73117 164 46612773
Arthropathy 19.25 10.52 68 73057 84632 46528305
Hyperlipidaemia 19.23 10.52 3 73122 18536 46594401
Chest pain 19.19 10.52 180 72945 176144 46436793
Pulmonary hypertension 19.01 10.52 17 73108 35976 46576961
Oral herpes 18.83 10.52 70 73055 19320 46593617
Rheumatoid arthritis 18.80 10.52 264 72861 239951 46372986
Injury 18.61 10.52 25 73100 44002 46568935
Haemoglobin urine 18.51 10.52 7 73118 113 46612824
Respiratory failure 18.44 10.52 81 73044 94735 46518202
Distributive shock 18.43 10.52 11 73114 510 46612427
Distal intestinal obstruction syndrome 18.40 10.52 10 73115 387 46612550
Sleep disorder 18.39 10.52 131 72994 46664 46566273
Pharyngeal paraesthesia 18.37 10.52 15 73110 1155 46611782
Burnout syndrome 18.35 10.52 8 73117 189 46612748
Urine oxalate increased 18.16 10.52 8 73117 194 46612743
Rhabdomyolysis 18.06 10.52 120 73005 41789 46571148
Injection site swelling 17.97 10.52 22 73103 40305 46572632
Bulimia nervosa 17.97 10.52 11 73114 534 46612403
Band neutrophil percentage increased 17.86 10.52 8 73117 202 46612735
Exposure during pregnancy 17.84 10.52 98 73027 108114 46504823
Persecutory delusion 17.82 10.52 21 73104 2534 46610403
Tooth hypoplasia 17.80 10.52 6 73119 68 46612869
Adrenal insufficiency 17.76 10.52 53 73072 13071 46599866
Ill-defined disorder 17.63 10.52 86 73039 26741 46586196
Blister 17.57 10.52 125 73000 44506 46568431
Gait deviation 17.41 10.52 6 73119 73 46612864
Platelet count decreased 17.37 10.52 89 73036 99935 46513002
Thrombosis 17.18 10.52 39 73086 56030 46556907
Obstructive airways disorder 17.06 10.52 53 73072 13359 46599578
Occult blood 17.04 10.52 13 73112 907 46612030
Epilepsy 16.98 10.52 78 73047 23660 46589277
Blood glucose increased 16.91 10.52 57 73068 71956 46540981
Housebound 16.90 10.52 8 73117 230 46612707
Psychomotor retardation 16.87 10.52 23 73102 3210 46609727
Libido increased 16.75 10.52 12 73113 760 46612177
Drug withdrawal syndrome 16.73 10.52 86 73039 27298 46585639
Bradycardia 16.69 10.52 168 72957 66130 46546807
Pemphigoid 16.56 10.52 31 73094 5660 46607277
Chronic kidney disease 16.48 10.52 24 73101 40847 46572090
Newborn persistent pulmonary hypertension 16.39 10.52 6 73119 88 46612849
Substance use disorder 16.38 10.52 5 73120 40 46612897
Pain in extremity 16.33 10.52 296 72829 258384 46354553
Urinary sediment present 16.21 10.52 17 73108 1803 46611134
Self-injurious ideation 16.20 10.52 19 73106 2281 46610656
Neuroleptic malignant syndrome 16.09 10.52 46 73079 11076 46601861
Glossodynia 16.06 10.52 28 73097 44345 46568592
Granulomatous liver disease 16.02 10.52 12 73113 814 46612123
Hypotonia 15.98 10.52 38 73087 8191 46604746
Cholinergic syndrome 15.97 10.52 9 73116 374 46612563
Ligament pain 15.84 10.52 7 73118 171 46612766
Loss of personal independence in daily activities 15.78 10.52 42 73083 57141 46555796
Therapeutic product effect incomplete 15.66 10.52 66 73059 78087 46534850
Heart rate decreased 15.63 10.52 94 73031 31629 46581308
Retinal depigmentation 15.62 10.52 8 73117 274 46612663
Wound 15.50 10.52 27 73098 42775 46570162
Victim of chemical submission 15.48 10.52 8 73117 279 46612658
Torsade de pointes 15.43 10.52 48 73077 12106 46600831
Calcium deficiency 15.43 10.52 12 73113 861 46612076
Sudden death 15.43 10.52 41 73084 9463 46603474
Tearfulness 15.25 10.52 25 73100 4110 46608827
Sopor 15.20 10.52 6 73119 19822 46593115
Muscle twitching 15.12 10.52 54 73071 14618 46598319
Pulmonary function test abnormal 15.08 10.52 14 73111 1281 46611656
Pressure of speech 14.90 10.52 10 73115 570 46612367
Ovarian germ cell cancer stage II 14.88 10.52 5 73120 56 46612881
Drug detoxification 14.86 10.52 7 73118 199 46612738
Postmortem blood drug level increased 14.72 10.52 9 73116 436 46612501
Platelet disorder 14.64 10.52 15 73110 1548 46611389
Diabetic hyperosmolar coma 14.63 10.52 9 73116 441 46612496
Chest wall mass 14.57 10.52 5 73120 60 46612877
Glucocorticoids increased 14.42 10.52 6 73119 126 46612811
Ureteric obstruction 14.35 10.52 16 73109 1818 46611119
Amyotrophy 14.33 10.52 6 73119 128 46612809
Post-traumatic neck syndrome 14.31 10.52 14 73111 1367 46611570
Hypokalaemia 14.22 10.52 205 72920 87819 46525118
Band neutrophil count increased 14.17 10.52 8 73117 334 46612603
Nail ridging 14.13 10.52 7 73118 223 46612714
Failed induction of labour 14.10 10.52 8 73117 337 46612600
Rales 14.10 10.52 40 73085 9591 46603346
Atelectasis 13.89 10.52 6 73119 18784 46594153
Gait disturbance 13.85 10.52 153 72972 145110 46467827
Neutrophil percentage increased 13.85 10.52 19 73106 2668 46610269
Myelocyte count increased 13.80 10.52 8 73117 351 46612586
Glomerular filtration rate decreased 13.77 10.52 45 73080 11649 46601288
Pruritus 13.76 10.52 486 72639 241866 46371071
Drug resistance 13.74 10.52 5 73120 17363 46595574
Respiratory acidosis 13.72 10.52 30 73095 6118 46606819
Rash scarlatiniform 13.60 10.52 6 73119 146 46612791
Blood creatine phosphokinase increased 13.56 10.52 82 73043 27642 46585295
Chemical submission 13.52 10.52 7 73118 245 46612692
Electrocardiogram repolarisation abnormality 13.44 10.52 13 73112 1252 46611685
Urinary tract obstruction 13.32 10.52 15 73110 1723 46611214
Concussion 13.23 10.52 32 73093 6971 46605966
Oedema 13.22 10.52 57 73068 67014 46545923
Hallucination, auditory 13.22 10.52 42 73083 10714 46602223
Social anxiety disorder 13.21 10.52 8 73117 381 46612556
Throat irritation 13.21 10.52 84 73041 28817 46584120
Strabismus 13.15 10.52 15 73110 1747 46611190
Device dislocation 13.15 10.52 9 73116 21793 46591144
Sensory level abnormal 13.09 10.52 6 73119 160 46612777
Clostridium difficile infection 13.08 10.52 12 73113 25091 46587846
Nausea 12.99 10.52 915 72210 686539 45926398
Tumour marker abnormal 12.96 10.52 6 73119 164 46612773
Soft tissue injury 12.92 10.52 11 73114 898 46612039
Pancreatic carcinoma recurrent 12.88 10.52 5 73120 87 46612850
Restlessness 12.81 10.52 76 73049 25448 46587489
Eye irritation 12.78 10.52 5 73120 16609 46596328
Lip blister 12.75 10.52 16 73109 2059 46610878
Biliary sepsis 12.70 10.52 9 73116 560 46612377
Panic attack 12.67 10.52 64 73061 20178 46592759
Thyroid adenoma 12.66 10.52 6 73119 173 46612764
Hostility 12.63 10.52 13 73112 1349 46611588
Osteonecrosis 12.61 10.52 13 73112 25731 46587206
Anaphylactic reaction 12.50 10.52 42 73083 53070 46559867
Vaginal haemorrhage 12.46 10.52 13 73112 25591 46587346
White blood cell count decreased 12.44 10.52 114 73011 112117 46500820
Bladder dilatation 12.44 10.52 10 73115 753 46612184
Device issue 12.39 10.52 8 73117 19972 46592965
Menopause 12.37 10.52 16 73109 2123 46610814
Dyspnoea exertional 12.36 10.52 39 73086 50250 46562687
Gallbladder disorder 12.30 10.52 6 73119 17492 46595445
Completed suicide 12.26 10.52 158 72967 145762 46467175
Specific gravity urine decreased 12.22 10.52 8 73117 437 46612500
Respiratory depression 12.22 10.52 43 73082 11557 46601380
Suicidal behaviour 12.15 10.52 17 73108 2431 46610506
Thirst decreased 12.14 10.52 6 73119 190 46612747
Personality change 12.13 10.52 26 73099 5232 46607705
Water intoxication 11.96 10.52 8 73117 453 46612484
Enanthema 11.96 10.52 8 73117 453 46612484
Subdural haematoma 11.86 10.52 46 73079 12951 46599986
Procedural pain 11.86 10.52 3 73122 13176 46599761
Withdrawal syndrome 11.82 10.52 58 73067 18076 46594861
Infusion site scar 11.81 10.52 6 73119 202 46612735
Hepatitis fulminant 11.78 10.52 20 73105 3382 46609555
Oropharyngeal blistering 11.68 10.52 10 73115 822 46612115
Camptocormia 11.51 10.52 6 73119 213 46612724
Body mass index decreased 11.49 10.52 7 73118 337 46612600
Developmental hip dysplasia 11.45 10.52 12 73113 1271 46611666
Sinusitis 11.43 10.52 275 72850 129493 46483444
Gamma-glutamyltransferase increased 11.41 10.52 87 73038 31653 46581284
Eosinophil count decreased 11.41 10.52 13 73112 1513 46611424
Anticonvulsant drug level above therapeutic 11.39 10.52 8 73117 491 46612446
Drug diversion 11.38 10.52 10 73115 851 46612086
Neoplasm malignant 11.36 10.52 12 73113 23487 46589450
Dysphagia 11.30 10.52 177 72948 77135 46535802
Acute kidney injury 11.25 10.52 464 72661 235391 46377546
Incoherent 11.21 10.52 23 73102 4489 46608448
Agoraphobia 11.13 10.52 7 73118 357 46612580
Tri-iodothyronine free decreased 11.12 10.52 6 73119 229 46612708
Meningitis herpes 11.12 10.52 6 73119 229 46612708
Cardiogenic shock 11.11 10.52 53 73072 16331 46596606
Urethral haemorrhage 11.10 10.52 4 73121 56 46612881
Pelvic prolapse 11.08 10.52 8 73117 513 46612424
Melaena 11.06 10.52 78 73047 27694 46585243
Potentiating drug interaction 10.95 10.52 21 73104 3902 46609035
Haematemesis 10.95 10.52 80 73045 28726 46584211
Lymphocyte percentage decreased 10.89 10.52 17 73108 2682 46610255
Poor quality sleep 10.82 10.52 50 73075 15203 46597734
Lower limb fracture 10.82 10.52 3 73122 12395 46600542
COVID-19 10.77 10.52 8 73117 18567 46594370
Neurotoxicity 10.76 10.52 4 73121 13713 46599224
Atrial fibrillation 10.73 10.52 107 73018 103483 46509454
Cardiac valve disease 10.73 10.52 21 73104 3963 46608974
Condition aggravated 10.71 10.52 297 72828 244755 46368182
Bradypnoea 10.70 10.52 18 73107 3021 46609916
Deep vein thrombosis 10.69 10.52 77 73048 79696 46533241
Negativism 10.65 10.52 7 73118 385 46612552
Foetal death 10.62 10.52 34 73091 8709 46604228
Illness anxiety disorder 10.59 10.52 5 73120 143 46612794
Parophthalmia 10.57 10.52 6 73119 253 46612684
Bronchopulmonary aspergillosis allergic 10.54 10.52 9 73116 737 46612200

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Coma 286.96 11.32 315 40983 40134 29871046
Depression 259.99 11.32 455 40843 89982 29821198
Drug interaction 239.53 11.32 709 40589 198859 29712321
Poisoning deliberate 235.74 11.32 129 41169 5775 29905405
Intentional overdose 220.94 11.32 279 41019 41202 29869978
Somnolence 158.27 11.32 386 40912 96377 29814803
Suicide attempt 128.52 11.32 202 41096 36495 29874685
Intentional self-injury 125.87 11.32 122 41176 13410 29897770
Overdose 109.73 11.32 309 40989 84028 29827152
Confusional state 108.88 11.32 420 40878 134414 29776766
Hypothermia 101.90 11.32 93 41205 9474 29901706
Toxicity to various agents 99.62 11.32 495 40803 176688 29734492
Electrocardiogram QT prolonged 97.19 11.32 176 41122 35659 29875521
Hepatocellular injury 88.86 11.32 140 41158 25331 29885849
Suicidal ideation 76.71 11.32 160 41138 35954 29875226
Prescription form tampering 76.43 11.32 29 41269 541 29910639
Drug dependence 74.21 11.32 117 41181 21178 29890002
Miosis 70.23 11.32 69 41229 7707 29903473
Neuroleptic malignant syndrome 68.88 11.32 98 41200 16197 29894983
Product dose omission issue 60.96 11.32 25 41273 91606 29819574
Cardiac failure congestive 59.53 11.32 21 41277 84386 29826794
Agitation 57.84 11.32 185 41113 53888 29857292
Blood mercury abnormal 54.65 11.32 17 41281 168 29911012
Withdrawal syndrome 54.08 11.32 72 41226 11178 29900002
Cholestasis 53.50 11.32 111 41187 24839 29886341
Housebound 53.26 11.32 17 41281 184 29910996
5-hydroxyindolacetic acid in urine increased 52.53 11.32 17 41281 193 29910987
Fall 49.83 11.32 424 40874 181448 29729732
Low density lipoprotein decreased 49.28 11.32 25 41273 956 29910224
Hyperthermia 47.57 11.32 64 41234 10035 29901145
Drug ineffective 41.58 11.32 287 41011 340100 29571080
Death 40.86 11.32 307 40991 356976 29554204
Bradypnoea 40.69 11.32 28 41270 1893 29909287
Disease progression 38.65 11.32 32 41266 79842 29831338
Myocardial infarction 38.13 11.32 72 41226 125553 29785627
Mental status changes 36.96 11.32 4 41294 37075 29874105
Agranulocytosis 36.25 11.32 88 41210 21854 29889326
Pneumonia aspiration 35.70 11.32 124 41174 37656 29873524
Macrophages increased 35.19 11.32 12 41286 162 29911018
Dysarthria 35.05 11.32 107 41191 30383 29880797
Thrombosis 34.38 11.32 8 41290 42223 29868957
Cerebral artery thrombosis 34.38 11.32 16 41282 505 29910675
Drug hypersensitivity 32.48 11.32 28 41270 68491 29842689
Altered state of consciousness 31.97 11.32 79 41219 19840 29891340
Insomnia 31.21 11.32 228 41070 93108 29818072
Pneumonia 31.12 11.32 303 40995 334003 29577177
Dystonic tremor 31.02 11.32 10 41288 112 29911068
Restlessness 30.50 11.32 84 41214 22515 29888665
Burnout syndrome 30.25 11.32 10 41288 122 29911058
Tremor 29.89 11.32 192 41106 75171 29836009
Disturbance in attention 29.61 11.32 82 41216 22047 29889133
Coma scale abnormal 28.72 11.32 29 41269 3347 29907833
Akathisia 28.70 11.32 38 41260 5866 29905314
Muscle rigidity 28.56 11.32 51 41247 10210 29900970
General physical health deterioration 28.35 11.32 235 41063 99709 29811471
Purpura 28.34 11.32 50 41248 9917 29901263
Gamma-glutamyltransferase increased 28.31 11.32 97 41201 29253 29881927
Neutrophil count increased 28.08 11.32 64 41234 15259 29895921
Faecaloma 27.26 11.32 32 41266 4373 29906807
Implant site extravasation 27.20 11.32 13 41285 436 29910744
Bradycardia 26.63 11.32 168 41130 65358 29845822
Drug monitoring procedure incorrectly performed 26.58 11.32 10 41288 182 29910998
Toxic skin eruption 25.98 11.32 51 41247 10964 29900216
Hepatic neoplasm 25.74 11.32 21 41277 1838 29909342
Dystonia 25.37 11.32 47 41251 9680 29901500
Disorientation 25.36 11.32 98 41200 31320 29879860
Brain scan abnormal 25.32 11.32 14 41284 639 29910541
Epilepsy 25.29 11.32 73 41225 20096 29891084
Sedation 25.29 11.32 64 41234 16309 29894871
Serum ferritin abnormal 25.22 11.32 10 41288 211 29910969
Extrapyramidal disorder 24.61 11.32 49 41249 10644 29900536
Respiratory failure 24.54 11.32 65 41233 100577 29810603
Restless legs syndrome 24.26 11.32 38 41260 6834 29904346
Electrocardiogram abnormal 24.25 11.32 35 41263 5857 29905323
Injection site pain 24.16 11.32 6 41292 30304 29880876
Puncture site haematoma 23.91 11.32 9 41289 164 29911016
Accessory spleen 23.76 11.32 9 41289 167 29911013
Contraindicated product administered 23.20 11.32 64 41234 17167 29894013
Bladder dilatation 22.90 11.32 17 41281 1295 29909885
Plasma cell myeloma 22.81 11.32 24 41274 53438 29857742
Antiphospholipid antibodies positive 22.43 11.32 10 41288 285 29910895
Dyspnoea 21.83 11.32 326 40972 332969 29578211
Depressed mood 21.70 11.32 62 41236 16967 29894213
Coronary artery disease 21.57 11.32 22 41276 49690 29861490
Malaise 21.40 11.32 336 40962 166626 29744554
Aggression 21.26 11.32 104 41194 36803 29874377
Loss of consciousness 21.11 11.32 184 41114 79191 29831989
Alcohol poisoning 21.09 11.32 26 41272 3738 29907442
Blepharospasm 20.81 11.32 14 41284 912 29910268
Diarrhoea 20.79 11.32 330 40968 333773 29577407
Paraneoplastic rash 20.63 11.32 7 41291 93 29911087
Blood ethanol increased 20.29 11.32 10 41288 359 29910821
Dextrocardia 20.16 11.32 8 41290 169 29911011
Cough 20.05 11.32 97 41201 125545 29785635
Logorrhoea 19.78 11.32 19 41279 2063 29909117
Loss of personal independence in daily activities 19.75 11.32 70 41228 21465 29889715
Substance abuse 19.60 11.32 35 41263 7005 29904175
Optic nerve cupping 19.59 11.32 6 41292 56 29911124
Blood creatine phosphokinase increased 19.44 11.32 115 41183 43733 29867447
Foetal alcohol syndrome 18.84 11.32 8 41290 202 29910978
Hospitalisation 18.79 11.32 20 41278 44299 29866881
Gastrointestinal haemorrhage 18.77 11.32 56 41242 83390 29827790
Normochromic normocytic anaemia 18.45 11.32 25 41273 3945 29907235
Conjunctival hyperaemia 18.42 11.32 19 41279 2248 29908932
Spinal cord haemorrhage 18.16 11.32 9 41289 327 29910853
Cell death 18.12 11.32 19 41279 2292 29908888
Depressed level of consciousness 18.09 11.32 102 41196 38120 29873060
Therapy non-responder 18.06 11.32 9 41289 29444 29881736
Pemphigoid 17.93 11.32 35 41263 7493 29903687
Anxiety 17.85 11.32 196 41102 89675 29821505
Clumsiness 17.81 11.32 15 41283 1372 29909808
Speech disorder 17.81 11.32 74 41224 24438 29886742
Drug intolerance 17.70 11.32 115 41183 45176 29866004
Adverse drug reaction 17.65 11.32 5 41293 23140 29888040
Eosinophil percentage increased 17.16 11.32 10 41288 505 29910675
Obsessive thoughts 17.16 11.32 11 41287 660 29910520
Pain 17.06 11.32 154 41144 172487 29738693
Sensorimotor disorder 17.05 11.32 9 41289 374 29910806
Peripheral swelling 16.81 11.32 37 41261 61037 29850143
Femoral artery aneurysm 16.44 11.32 7 41291 178 29911002
Product quality issue 16.43 11.32 3 41295 18771 29892409
Blood pressure systolic increased 16.41 11.32 52 41246 15058 29896122
Parkinsonism 16.35 11.32 33 41265 7236 29903944
Erythrosis 16.20 11.32 5 41293 48 29911132
Tachycardia 16.13 11.32 164 41134 73575 29837605
Implant site infection 16.13 11.32 12 41286 917 29910263
Lymphocyte percentage decreased 16.08 11.32 17 41281 2069 29909111
Vascular purpura 15.99 11.32 15 41283 1582 29909598
Reading disorder 15.94 11.32 8 41290 299 29910881
Mean cell haemoglobin concentration increased 15.91 11.32 8 41290 300 29910880
Band neutrophil percentage increased 15.86 11.32 6 41292 111 29911069
Jaundice cholestatic 15.84 11.32 25 41273 4526 29906654
Neutrophil percentage increased 15.83 11.32 16 41282 1848 29909332
Dermatitis psoriasiform 15.73 11.32 13 41285 1158 29910022
Asthenia 15.67 11.32 213 41085 221077 29690103
Congenital hand malformation 15.40 11.32 9 41289 457 29910723
Nausea 15.36 11.32 303 40995 296654 29614526
Arteriovenous fistula 15.29 11.32 10 41288 621 29910559
Urine leukocyte esterase positive 15.26 11.32 8 41290 328 29910852
Hypoglycaemia 15.04 11.32 121 41177 50860 29860320
Psychotic disorder 14.89 11.32 64 41234 21451 29889729
Homicide 14.87 11.32 12 41286 1034 29910146
Laboratory test abnormal 14.81 11.32 3 41295 17439 29893741
Respiratory depression 14.77 11.32 42 41256 11461 29899719
Sudden death 14.76 11.32 51 41247 15441 29895739
Neuropathy peripheral 14.65 11.32 49 41249 70426 29840754
Somnambulism 14.58 11.32 20 41278 3194 29907986
Capillary fragility 14.50 11.32 5 41293 70 29911110
Spleen congestion 14.41 11.32 8 41290 368 29910812
Musculoskeletal pain 14.22 11.32 13 41285 30927 29880253
Drug resistance 14.20 11.32 5 41293 20128 29891052
Rhabdomyolysis 14.19 11.32 142 41156 63438 29847742
Rash maculo-papular 14.19 11.32 71 41227 25347 29885833
pH urine increased 14.12 11.32 5 41293 76 29911104
Opiates positive 14.01 11.32 7 41291 259 29910921
Respiratory arrest 13.80 11.32 12 41286 29246 29881934
Tooth injury 13.73 11.32 10 41288 740 29910440
Delirium febrile 13.72 11.32 4 41294 31 29911149
Prothrombin level decreased 13.59 11.32 12 41286 1170 29910010
Drug therapy enhancement 13.48 11.32 3 41295 6 29911174
Intra-abdominal fluid collection 13.45 11.32 12 41286 1186 29909994
Haemorrhage 13.45 11.32 27 41271 46052 29865128
Mania 13.33 11.32 35 41263 9119 29902061
Expired product administered 13.23 11.32 18 41280 2851 29908329
General symptom 12.87 11.32 10 41288 816 29910364
Myoclonus 12.83 11.32 44 41254 13268 29897912
Pyrexia 12.76 11.32 309 40989 294180 29617000
Therapeutic response decreased 12.73 11.32 9 41289 24340 29886840
Poverty of thought content 12.64 11.32 4 41294 42 29911138
Dyssomnia 12.47 11.32 4 41294 44 29911136
Areflexia 12.45 11.32 17 41281 2702 29908478
Blood urea increased 12.39 11.32 15 41283 31366 29879814
Adrenocortical insufficiency acute 12.32 11.32 12 41286 1325 29909855
Abdominal compartment syndrome 12.30 11.32 10 41288 871 29910309
Hyponatraemia 12.18 11.32 144 41154 67058 29844122
Sinusitis 12.07 11.32 17 41281 33328 29877852
Chronic kidney disease 12.07 11.32 21 41277 37817 29873363
Cytomegalovirus infection 12.05 11.32 9 41289 23665 29887515
Staphylococcal impetigo 11.95 11.32 3 41295 12 29911168
Hypercapnia 11.94 11.32 20 41278 3804 29907376
Exhibitionism 11.94 11.32 4 41294 51 29911129
Paranoia 11.93 11.32 36 41262 10152 29901028
Band neutrophil count increased 11.86 11.32 6 41292 228 29910952
Acute respiratory failure 11.72 11.32 11 41287 25839 29885341
Hypomania 11.71 11.32 15 41283 2241 29908939
COVID-19 11.68 11.32 5 41293 17873 29893307
Fatigue 11.67 11.32 345 40953 320328 29590852
Psychomotor skills impaired 11.62 11.32 14 41284 1965 29909215
Muscle spasms 11.57 11.32 48 41250 64790 29846390
Asphyxia 11.46 11.32 24 41274 5401 29905779
Bradyphrenia 11.44 11.32 20 41278 3937 29907243
Intentional device misuse 11.40 11.32 6 41292 248 29910932
Myocarditis 11.38 11.32 35 41263 9976 29901204

Pharmacologic Action:

SourceCodeDescription
ATC N05CF01 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Benzodiazepine related drugs
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D006993 Hypnotics and Sedatives
CHEBI has role CHEBI:35488 cns depressants
CHEBI has role CHEBI:35717 sedatives

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Insomnia indication 193462001
Suicidal thoughts contraindication 6471006
Asthenia contraindication 13791008
Alcohol intoxication contraindication 25702006
Depressive disorder contraindication 35489007
Hepatic failure contraindication 59927004
Sleep automatism contraindication 247962006
Severe chronic obstructive pulmonary disease contraindication 313299006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.95 Basic
pKa2 2.26 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
GABA-A receptor alpha-5/beta-3/gamma-2 Ion channel POSITIVE MODULATOR Ki 7.28 WOMBAT-PK DRUG LABEL
GABA A receptor alpha-3/beta-2/gamma-2 Ion channel POSITIVE MODULATOR Ki 6.58 WOMBAT-PK DRUG LABEL
GABA A receptor alpha-3/beta-2/gamma-3 Ion channel POSITIVE MODULATOR Ki 6.49 WOMBAT-PK DRUG LABEL
GABA-A receptor alpha-1/beta-2/gamma-3 Ion channel POSITIVE MODULATOR Ki 7.15 WOMBAT-PK DRUG LABEL
GABA A receptor alpha-5/beta-2/gamma-2 Ion channel POSITIVE MODULATOR Ki 7.28 WOMBAT-PK DRUG LABEL
GABA A receptor alpha-5/beta-2/gamma-3 Ion channel POSITIVE MODULATOR Ki 6.75 WOMBAT-PK DRUG LABEL
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE MODULATOR Ki 7.18 WOMBAT-PK DRUG LABEL
GABA A receptor alpha-5/beta-3/gamma-3 Ion channel POSITIVE MODULATOR Ki 6.75 WOMBAT-PK DRUG LABEL
GABA-A receptor; anion channel Ion channel IC50 7.54 CHEMBL

External reference:

IDSource
D01372 KEGG_DRUG
C0592282 UMLSCUI
CHEBI:53762 CHEBI
ZPC PDB_CHEM_ID
CHEMBL135400 ChEMBL_ID
C515050 MESH_SUPPLEMENTAL_RECORD_UI
4462 INN_ID
03A5ORL08Q UNII
5735 PUBCHEM_CID
7430 IUPHAR_LIGAND_ID
DB01198 DRUGBANK_ID
152527 RXNORM
003775 NDDF
321174005 SNOMEDCT_US
395929002 SNOMEDCT_US

Pharmaceutical products:

None